FibroGen/ US31572Q8087 /

9/25/2023 9:59:43 PM	Chg. +0.06	Volume	Bid-	Ask-	High	Low
0.85USD	+7.14%	34,996 Turnover: 29,560	-Bid Size: -	-Ask Size: -	0.87	0.77

GlobeNewswire 2/28/2022 FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2/14/2022 FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2/4/2022 FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

GlobeNewswire 1/4/2022 FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

GlobeNewswire 12/20/2021 FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

GlobeNewswire 11/15/2021 EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel

GlobeNewswire 11/9/2021 FibroGen Reports Third Quarter 2021 Financial Results

GlobeNewswire 11/2/2021 FibroGen to Present at Upcoming Investor Conferences

GlobeNewswire 10/26/2021 FibroGen to Report Third Quarter 2021 Financial Results

GlobeNewswire 10/25/2021 FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology...

GlobeNewswire 8/25/2021 FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatm...

GlobeNewswire 8/20/2021 Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Pa...

GlobeNewswire 8/16/2021 FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Offi...

GlobeNewswire 8/12/2021 Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

GlobeNewswire 8/11/2021 FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney ...

GlobeNewswire 8/9/2021 FibroGen Reports Second Quarter 2021 Financial Results

GlobeNewswire 7/29/2021 FibroGen to Report Second Quarter 2021 Financial Results

GlobeNewswire 7/19/2021 Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant ...

GlobeNewswire 7/16/2021 FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of...

GlobeNewswire 7/12/2021 FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

GlobeNewswire 6/25/2021 Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomati...

GlobeNewswire 6/17/2021 FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Pa...

GlobeNewswire 6/16/2021 Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform

GlobeNewswire 6/15/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroG...

GlobeNewswire 6/11/2021 FGEN FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with...